Vertex Buys Semma, Gaining Cell Therapy-Based Type 1 Diabetes Treatments

 
• By Jessica Merrill
  
Generate a summary of this article
Listen to this article
Beta

Semma's innovative technology involves growing insulin-producing beta cells from stem cells and transplanting them into the liver, but it hasn't been tested in humans yet.

Diabetes concept

Vertex Pharmaceuticals Inc. is building out its early pipeline beyond cystic fibrosis with the $950m acquisition of Semma Therapeutics Inc., a privately-held cell therapy company working in type 1 diabetes. Semma is pioneering a novel and potentially curative approach to treating type 1 diabetes based on the development of insulin-producing beta cells grown from stem cells that can restore insulin secretion.

Semma's technology is early stage, having only been tested in animal models, but two lead programs have demonstrated preclinical proof-of-concept,...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Deals

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.